Westminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
Westminster Pharmaceuticals is recalling specific lots of Irbesartan Tablets because FDA testing found traces of the NDEA impurity.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for drug recalls involving impurities.
Plain-English summary
Westminster Pharmaceuticals, LLC is recalling specific lots of Westminster Irbesartan Tablets, USP 150 mg. The affected products are available in 30-count and 90-count bottles. The recall covers 2,319 bottles distributed nationwide.
The recall was initiated because FDA laboratory testing confirmed the presence of traces of the NDEA impurity in these specific lots. This finding represents a deviation from Current Good Manufacturing Practices (CGMP).
Consumers who have these specific products should stop using them and contact their healthcare provider or pharmacist for guidance. The affected batch numbers and expiration dates are listed in the official recall notice.
The recalled product
- Product
- Westminster Irbesartan Tablets, USP 150 mg Rx Only Manufactured by: ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Manufactured for: Westminster Pharmaceuticals, LLC. Olive Branch, MS 38654 a) 30 count bottle NDC 69367-120-01; b) 90 count bottle NDC 69367-120-03
- Manufacturer
- Westminster Pharmaceuticals Llc
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 2,319
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Batch Numbers: a) B161005A Exp. 09/30/2019
- C161002A Exp. 02/29/2020
- b) B161005B Exp. 09/30/2019
- C161002B Exp. 02/29/2020
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Westminster Pharmaceuticals Llc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Westminster Pharmaceuticals Llc
See all →- HighMetoprolol tartrate tablets recalled for nitrosamine above acceptable daily intake level
FDA (Drugs) · 2025-08-20
- HighMetoprolol tartrate 100 mg tablets exceed the nitrosamine daily intake level
FDA (Drugs) · 2025-08-20
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
FDA (Drugs) · 2018-12-19
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- CriticalFDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
FDA (Drugs) · 2018-08-29
Same hazard · ndeA impurity
See all →- SevereMylan Recalls Amlodipine and Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- SevereTeva Recalls Amlodipine and Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19